Fennec Pharmaceuticals Inc.

TSX:FRX Stock Report

Market Cap: CA$522.0m

Fennec Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

TSX:FRX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 Sep 26SellCA$202,217Pierre SayadIndividual12,000CA$16.85
31 Aug 26SellCA$202,631Pierre SayadIndividual12,000CA$16.89
28 Aug 26BuyCA$155,378Robert AndradeIndividual21,928CA$7.09
27 Aug 26SellCA$1,746,272Robert AndradeIndividual106,844CA$16.34
01 Jun 26BuyCA$52,850Rostislav RaykovIndividual18,375CA$3.39
01 Jun 26SellCA$129,683Rostislav RaykovIndividual9,747CA$13.30
01 Apr 26BuyCA$53,074Rostislav RaykovIndividual15,598CA$3.40
01 Apr 26SellCA$95,925Rostislav RaykovIndividual10,946CA$8.76
30 Mar 26BuyCA$27,682Christiana CioffiIndividual4,700CA$5.89
02 Mar 26BuyCA$52,401Rostislav RaykovIndividual20,806CA$3.36
02 Mar 26SellCA$115,677Rostislav RaykovIndividual10,079CA$11.48
19 Feb 26BuyCA$13,683Robert AndradeIndividual29,735CA$5.58
14 Jan 26BuyCA$33,993Robert AndradeIndividual10,000CA$3.40
07 Jan 26BuyCA$48,040Robert AndradeIndividual14,184CA$3.39
24 Dec 25SellCA$10,258,200Southpoint Capital Advisors LPCompany1,000,000CA$10.26
18 Nov 25SellCA$238,128Southpoint Capital Advisors LPCompany19,341CA$12.31
17 Nov 25SellCA$2,855,595Southpoint Capital Advisors LPCompany246,018CA$12.33
17 Nov 25SellCA$2,855,595Southpoint Capital Advisors LPCompany246,018CA$12.33
10 Oct 25BuyCA$6,994Chris RallisIndividual4,062CA$1.72
10 Oct 25SellCA$22,958Chris RallisIndividual1,775CA$12.93
09 Oct 25SellCA$891,840Southpoint Capital Advisors LPCompany67,114CA$13.44
09 Oct 25SellCA$891,758Southpoint Capital Advisors LPCompany67,114CA$13.44
08 Oct 25BuyCA$15,757Rostislav RaykovIndividual4,609CA$3.42

Insider Trading Volume

Insider Buying: FRX insiders have sold more shares than they have bought in the past 3 months.

Ownership Breakdown

What is the ownership structure of FRX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,022,1082.91%
Private Companies3,993,69411.4%
Institutions8,878,71425.3%
Hedge Funds10,170,76229%
General Public11,001,88131.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26%.

Top Shareholders

Top 25 shareholders own 61.84% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.4%
Alfasigma S.p.A.
3,993,694CA$59.4m0%no data
9.09%
Rosalind Advisors, Inc.
3,188,001CA$47.5m9.62%11.44%
7.44%
Sonic GP LLC
2,607,357CA$38.8m0%100.0%
7.09%
Aigh Capital Management, LLC
2,486,038CA$37.0m25.5%2.98%
5.39%
Solas Capital Management, LLC
1,889,366CA$28.1m-23.9%10.68%
4.93%
BlackRock, Inc.
1,727,069CA$25.7m26.2%no data
3.31%
AWM Investment Company Inc
1,160,296CA$17.3m61.1%1.37%
2.52%
Vanguard Capital Management, LLC
884,706CA$13.2m-5.47%no data
1.42%
Prospect Capital Advisors, LLC
497,800CA$7.4m0%2.5%
1.21%
State Street Investment Management
426,004CA$6.3m18.7%no data
1.15%
Geode Capital Management, LLC
402,566CA$6.0m8.29%no data
0.69%
Robert Andrade
241,306CA$3.6m-17.1%no data
0.67%
Jane Street Group, LLC
233,877CA$3.5m0%no data
0.64%
Potomac Capital Management Inc.
224,400CA$3.3m0%2.01%
0.61%
Khalid Islam
213,825CA$3.2m0%no data
0.57%
Vanguard Portfolio Management, LLC
199,998CA$3.0m18.7%no data
0.55%
Kam Lawrence
192,602CA$2.9m0%no data
0.52%
Eaton Vance Management
182,070CA$2.7m2.85%no data
0.48%
Northern Trust Global Investments
167,922CA$2.5m10.4%no data
0.4%
Marshall Wace LLP
138,758CA$2.1m0%no data
0.38%
Renaissance Technologies LLC
134,200CA$2.0m0%no data
0.37%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
131,482CA$2.0m116%no data
0.35%
Rostislav Raykov
124,411CA$1.9m0%no data
0.34%
Trexquant Investment LP
119,122CA$1.8m130%0.01%
0.34%
Centerbook Partners LP
118,582CA$1.8m0%0.07%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/16 09:47
End of Day Share Price 2026/09/16 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Fennec Pharmaceuticals Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Madison Wynne El-SaadiB. Riley Securities, Inc.
Naureen QuibriaCapital One Securities, Inc.